Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
India has taken the lead in recognising NAFLD as a major non-communicable disease
Quinidine Sulphate helps manage rare irregular heartbeat conditions
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Dyslipidemia is a critical risk factor for cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
